FDA Approved: JARDIANCE — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Jardiance (empagliflozin) submitted by Boehringer Ingelheim Pharmaceuticals, Inc., resulting in updated labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Jardiance (empagliflozin)

Snippet

SUPPL AP for JARDIANCE (EMPAGLIFLOZIN)